BGLC vs TECH · rev $9.5M vs P/E 65, rev $1.22B
BioNexus Gene Lab Corp Common stock (BGLC) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported BGLC revenue for 2024-12-31 was $9.5M. Net income was $1.6M. Revenue was down 2.7% from 2023-12-31 to 2024-12-31. BGLC currently screens at market cap $6.1M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
BGLC currently screens at market cap $6.1M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the BGLC and TECH stock pages for the full models.
Not investment advice.